The SACRA (SGLT-2i and ARB Combination Therapy in Patients with T2DM and Nocturnal Hypertension) study attempted to investigate the role of SGLT2 inhibitors in diabetes accompanying refractory nocturnal hypertension. The gene discussed is SLC5A2; the disease is diabetes mellitus.